Nexalin’s device improves symptoms of mild traumatic brain injury
Nexalin Technology has revealed positive data from a clinical trial that evaluated its neurostimulation device in veteran patients with combat-related…
Nexalin Technology has revealed positive data from a clinical trial that evaluated its neurostimulation device in veteran patients with combat-related…
The European Medicine’s Agency (EMA) has granted priority medicines (PRIME) status to 89bio’s pegozafermin, a drug being evaluated to treat…
The US Food and Drug Administration (FDA) has rejected Regeneron Pharmaceutical’s approval application for odronextamab in two forms of lymphoma,…
AriBio has signed off on exclusive marketing rights for its Alzheimer’s disease treatment candidate AR1001 in China. The deal, with…
Innate has dropped plans to evaluate lacutamab as a monotherapy in KIR3DL2-expressing refractory/relapsing peripheral T cell lymphoma (r/r PTCL) following…
Immuno-oncology company Nouscom has extended a Series C financing round to raise $82m (€75.8m) as it looks to advance its…
Reece Pharmaceuticals has completed the dosing of a cohort of healthy participants in its phase I/II trial evaluating its REECE327…
Neupulse, a UK-based company that is developing a wristband to help manage the symptoms of Tourette's syndrome, has raised $3.2m…
Pi Health has launched on the clinical trial software-as-a-service (SaaS) market after completing a $30m Series A funding. The US…
Israel-based pharma company SciSparc has kicked off a trial evaluating its SCI-210 compound in children and adolescents with autism spectrum…